Key Takeaways
Law firm Levi & Korsinsky has launched an investigation into TriSalus Life Sciences, Inc. (NASDAQ: TLSI) for potential securities law violations after the company reported first-quarter revenue of $8.9 million.
TriSalus attributed the 3.3 percent year-over-year revenue decline to a commercial team expansion. "Q1 performance was not a function of softer demand... It reflects the deliberate cost of a build-out phase," President and CEO Mary Szela said on the company's May 12 earnings call.
The medical technology firm's revenue fell from $9.2 million in the prior-year period. It also revised its full-year 2026 revenue guidance downward to $54–$57 million, citing the Q1 results and a delayed FDA clearance for its TriNav Advance device.
The investigation adds legal pressure as the company navigates a strategic expansion. Despite the revenue dip, TriSalus reported a swing to a $1.5 million net income from a $10.4 million loss a year earlier, largely due to non-cash gains from the remeasurement of warrant and earnout liabilities.
The company's balance sheet was strengthened in the quarter by a February equity offering that raised approximately $42.6 million in net proceeds. Cash and cash equivalents stood at $56.6 million as of March 31, 2026, which executives stated fully funds the company's strategic growth plan.
TriSalus is an oncology-focused company developing technology to improve drug delivery for solid tumors. The firm is expanding its commercial team to support its Pressure-Enabled Drug Delivery (PEDD) technology and its investigational immunotherapeutic, nelitolimod.
The investigation by Levi & Korsinsky creates uncertainty for investors at a time when TriSalus is attempting to scale its commercial operations. The next catalyst will be the FDA's decision on the TriNav Advance device, which the company still expects in the second half of 2026.
This article is for informational purposes only and does not constitute investment advice.
